EP165: Heart Conditions & Beta Blockers

Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients. Podcast Summary Dr. Warrick Bishop is a practicing cardiologist and author dedicated to educating patients about heart health. In this episode, he discusses four important cardiovascular topics: atrial fibrillation ablation, left atrial appendage occlusion devices, heart failure with preserved ejection fraction, and beta-blocker duration after heart attack. Key Takeaways: The KABANA trial (2,000+ patients over 5 years) showed that electrophysiological ablation reduced atrial fibrillation recurrence to 6% compared to 14% with drug therapy, though there was no difference in final health outcomes. Atrial fibrillation ablation is primarily beneficial for reducing symptoms rather than improving patient outcomes, particularly for asymptomatic patients. Left atrial appendage occlusion devices (like the Watchman) block the heart chamber where blood clots form during atrial fibrillation, offering an alternative to blood thinners for high-bleeding-risk patients. Recent studies on left atrial appendage closure devices show comparable but not definitively superior results to blood thinners, with questions remaining about study robustness. Blood thinners provide additional protective benefits beyond stroke prevention, including reduced risk of deep vein thrombosis and pulmonary embolism. Heart failure with preserved ejection fraction (a stiff heart that contracts normally but doesn't relax) is increasingly common with aging and is linked to high blood pressure and obesity, particularly in women. Milrinone, a phosphodiesterase inhibitor, shows early promise as a novel treatment for heart failure with preserved ejection fraction, though current evidence is preliminary with only small patient populations studied. Beta-blockers should be continued for at least one to two years after a heart attack to maintain cardiovascular benefits, with diminishing returns beyond two years.